These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16015505)

  • 1. Decitabine in chronic leukemias.
    Issa JP; Byrd JC
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S43-9. PubMed ID: 16015505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M
    Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
    Fenaux P
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
    Issa JP; Gharibyan V; Cortes J; Jelinek J; Morris G; Verstovsek S; Talpaz M; Garcia-Manero G; Kantarjian HM
    J Clin Oncol; 2005 Jun; 23(17):3948-56. PubMed ID: 15883410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
    Issa JP; Garcia-Manero G; Giles FJ; Mannari R; Thomas D; Faderl S; Bayar E; Lyons J; Rosenfeld CS; Cortes J; Kantarjian HM
    Blood; 2004 Mar; 103(5):1635-40. PubMed ID: 14604977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demethylating agents in myeloid malignancies.
    Garcia-Manero G
    Curr Opin Oncol; 2008 Nov; 20(6):705-10. PubMed ID: 18841054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
    Kantarjian HM; O'Brien SM; Keating M; Beran M; Estey E; Giralt S; Kornblau S; Rios MB; de Vos D; Talpaz M
    Leukemia; 1997 Oct; 11(10):1617-20. PubMed ID: 9324279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of decitabine with allogeneic progenitor cell transplantation.
    Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
    Leukemia; 1997 Mar; 11 Suppl 1():S32-4. PubMed ID: 9130690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
    de Lima M; Ravandi F; Shahjahan M; Andersson B; Couriel D; Donato M; Khouri I; Gajewski J; van Besien K; Champlin R; Giralt S; Kantarjian H
    Cancer; 2003 Mar; 97(5):1242-7. PubMed ID: 12599231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decitabine in myelodysplastic syndromes.
    Saba HI; Wijermans PW
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decitabine in acute myeloid leukemia.
    Lübbert M; Minden M
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S38-42. PubMed ID: 16015504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
    Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
    Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
    Drugs R D; 2003; 4(3):179-84. PubMed ID: 12757405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
    Drugs R D; 2003; 4(6):352-8. PubMed ID: 14584964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine.
    Daskalakis M; Blagitko-Dorfs N; Hackanson B
    Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine and its role in the treatment of hematopoietic malignancies.
    Plimack ER; Kantarjian HM; Issa JP
    Leuk Lymphoma; 2007 Aug; 48(8):1472-81. PubMed ID: 17701577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of decitabine in the treatment of myelodysplastic syndromes.
    Atallah E; Kantarjian H; Garcia-Manero G
    Expert Opin Pharmacother; 2007 Jan; 8(1):65-73. PubMed ID: 17163808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.